MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • CytRx Corp. (CYTR) Price Rally, Potential Mirrors Pharmacyclics (PCYC) Performance 0 comments
    Dec 13, 2013 2:07 PM | about stocks: CYTR

    It's quite a catching opener, especially if you're an investor with an interest in the biotech sector. It's also a bold statement, though one backed by weighty evidence. In an article published today, Wall Street Cheat Sheet contributor James Ratz begins with:

    "The biggest story this week in biotechnology has been the explosion seen in shares of CytRx Corporation (NASDAQ:CYTR). In fact, the recent move catapults CytRx to one of the top performing biotechnology stocks of 2013, and what's really interesting is that based on the recent news, CytRx may be on the verge of altering the cancer landscape …"

    Comparing CytRx' rally to a previous one stunted by Pharmacyclics (NASDAQ:PCYC), Ratz combs through the reasons both companies' ability to apply treatment to several diseases.

    To read the full article visit: wallstcheatsheet.com/stocks/is-cytrx-cor....html

    CytRx is developing aldoxorubicin as a potential alternative to the commonly used chemotherapeutic agent doxorubicin. Aldoxorubicin's primary application is for soft tissue sarcoma, followed by a variety of other cancers including glioblastoma multiforme and Kaposi's sarcoma.

    The company recently released the results of its ongoing phase 2b clinical trial in which aldoxorubicin met primary and secondary endpoints, boasting 80-100 percent superiority over doxorubicin in progression-free survival (NYSE:PFS).

    Adding to the obvious potential of these results, Ratz suggests that CytRx could be the "next Pharmacyclics" for three primary reasons:

    •Platform applicable to multiple diseases

    •"Smart Money" purchasing shares

    •Sudden share price explosion

    The article summarizes Pharmacyclics' developments and its stock's tremendous bull run started in 2011, as well as provides supporting evidence for Ratz's assessment before concluding that:

    "The similarities between CytRx and Pharmacyclics are hard to ignore. A world class platform that has the potential to cure millions and generate billions, a significant institutional interest, and a rapid share price explosion, all lend credence to the theory that CytRx may soon follow a similar path to Pharmacyclics. Dr. Gene Salkind and the other institutions on board are likely adding to their already massive holdings as I write this article, hoping that this run is just getting started."

    For more information visit cytrx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CYTR
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.